BCR‐ABL1 transcript levels at 4 weeks have prognostic significance for time‐specific responses and for predicting survival in chronic‐phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors

The present study aimed to assess the clinical impact of BCR‐ABL1 transcript levels determined at an earlier time point than the 3‐month early molecular response (EMR) in chronic‐phase chronic myeloid leukemia (CML‐CP) patients. BCR‐ABL1 transcript levels of CML‐CP patients (n = 258; median age, 43...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Hye‐young, Noh, Hayeon, Choi, Soo young, Lee, Sung‐Eun, Kim, Soo‐Hyun, Kee, Kyung‐Mi, Yoo, Hea‐Lyun, Lee, Mi‐young, Kang, Ki‐Hoon, Suh, Ji‐Hyung, Yang, Seon‐young, Jang, Eun‐Jung, Lee, Jangik I., Kim, Dong‐Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198233/
https://www.ncbi.nlm.nih.gov/pubmed/30171671
http://dx.doi.org/10.1002/cam4.1753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198233/
https://www.ncbi.nlm.nih.gov/pubmed/30171671
http://dx.doi.org/10.1002/cam4.1753

Ejemplares similares